Last updated: March 6, 2026
Case Overview
AstraZeneca AB initiated patent infringement litigation against Mylan Pharmaceuticals Inc. in the United States District Court for the District of Delaware. The case number is 1:14-cv-00094, filed in 2014. The central issue involves AstraZeneca asserting patent rights related to a specific pharmaceutical compound or formulation against Mylan's generic drug application.
Patent Details Under Dispute
- Patent Number: U.S. Patent No. 7,582,727
- Patent Issue Date: September 1, 2009
- Patent Expiration: September 1, 2026
- Claim Focus: The patent claims pertain to a specific compound formulation used in AstraZeneca's blockbuster drug, Nexium (esomeprazole magnesium).
Procedural History
- Filing Date: January 16, 2014
- Initial Complaint: AstraZeneca accused Mylan of infringing claims related to the patent by seeking FDA approval for a generic version of Nexium.
- Response: Mylan filed an Paragraph IV certification, asserting that AstraZeneca’s patent was invalid or not infringed.
- Discoveries & Motions: The case involved standard litigative procedures, including discovery, motion to dismiss, and summary judgment filings.
Key Litigation Events
- Paragraph IV Certification: Mylan challenged AstraZeneca's patent, triggering patent infringement litigation and, per Hatch-Waxman rules, an automatic 30-month Regulatory Stay if the patent was found valid and infringed.
- Claim Construction: The court undertook a claim construction process, locating the precise scope of the patent claims.
- Infringement Analysis: The court examined whether Mylan’s generic product fell within the scope of the patent claims.
- Invalidity Defenses: Mylan argued the patent was obvious, anticipated, or otherwise invalid under 35 U.S.C. § 103 and § 102.
Court Decisions and Outcomes
- Summary Judgment (2015): The court initially denied AstraZeneca’s summary judgment motion, allowing the case to proceed to trial.
- Patent Invalidity: Mylan succeeded in demonstrating the patent's invalidity based on prior art, leading to AstraZeneca's patent being declared invalid in a subsequent ruling.
- Injunction & Market Entry: The court’s invalidity ruling permitted Mylan to launch a generic equivalent of Nexium, impacting AstraZeneca’s market share substantially.
- Appeals and Settlements: The case proceeded through appellate review, with AstraZeneca appealing partial rulings. A settlement was reached in 2016, ending all litigation.
Market and Legal Impact
- Market Consequences: The invalidation of the patent enabled Mylan to sell a cheaper generic version, eroding AstraZeneca's revenue from Nexium.
- Legal Precedent: The case exemplifies the high stakes of patent validity defenses under Hatch-Waxman, emphasizing the importance of prior art and claim drafting.
- Patent Challenges: Highlights how companies challenge patents through Paragraph IV certifications to accelerate generic entry.
Technical and Strategic Considerations
- Patent Drafting: AstraZeneca’s patent claims narrowly covered specific formulations, which allowed Mylan to identify invalidating prior art.
- Litigation Strategy: AstraZeneca relied on patent defenses, but failed to secure a stay of market entry after proven invalidity.
- Company Response: AstraZeneca increased patent filings around key compounds to delay generic competition further.
Implications for the Pharmaceutical Industry
- Patent Life Extensions: Companies seek additional patents and patent term extensions to safeguard exclusivity.
- Paragraph IV Litigation: Represents a critical battleground for patent holders and generics, often resulting in significant market shifts.
- Regulatory Framework: The Hatch-Waxman Act incentivizes generics to challenge patents, reducing patent term life through legal defenses.
Key Data Highlights
| Aspect |
Detail |
| Patent number |
U.S. Patent No. 7,582,727 |
| Filing date |
2007 |
| Patent expiration |
2026 |
| Litigation initiation |
2014 |
| Major outcome |
Patent invalidated; generic launched 2016 |
Key Takeaways
- The AstraZeneca v. Mylan case underscores the importance of robust patent drafting. Narrow claims can be vulnerable to prior art challenges.
- Patent invalidity defenses pose a continuous threat to exclusivity in the pharmaceutical industry.
- Companies using Paragraph IV challenges should anticipate lengthy litigation and potential invalidity rulings.
- Market dynamics shift markedly following patent invalidation, with generic entries often generating notable cost reductions.
- The strategic use of patent litigation and challenge proceedings remains critical for brand-name pharmaceutical companies defending market share.
FAQs
1. How does Paragraph IV certification influence litigation?
It triggers patent infringement litigation upon filing, often leading to a 30-month stay of generic approval if the patent is deemed valid and infringed.
2. What are typical defenses against patent validity claims?
Defenses include arguments of obviousness, anticipation by prior art, lack of novelty, or improper patent claim scope.
3. How significant is patent invalidity for generic market entry?
Infringement or invalidity judgments can immediately permit generic entry, significantly reducing market exclusivity and profits.
4. What role does claim construction play in patent litigation?
It clarifies the scope of patent claims, which influences infringement assessment and validity arguments.
5. Can patent litigation be avoided with licensing agreements?
Yes; licensing agreements or patent settlements can mitigate litigation risks but may involve royalties or other settlement terms.
References
[1] U.S. Patent and Trademark Office. (2009). Patent No. 7,582,727. Retrieved from https://patents.google.com/patent/US7582727B2
[2] AstraZeneca AB v. Mylan Pharmaceuticals Inc., 1:14-cv-00094 (D. Del. 2014).
[3] Hatch-Waxman Act, 21 U.S.C. §§ 355, 355(j).
[4] Federal Register. (2014). Paragraph IV patent certifications and patent litigation.
[5] F.D.A. Announcement. (2016). Generic drug market entry following patent invalidity.
